SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals.

COVID-19 / prevention & control COVID-19 Vaccines Epitopes, T-Lymphocyte / genetics Humans RNA, Messenger / genetics SARS-CoV-2 / genetics Spike Glycoprotein, Coronavirus / genetics

Journal

Nature microbiology

ISSN: 2058-5276

Titre abrégé: Nat Microbiol

Pays: England

ID NLM: 101674869

Informations de publication

Date de publication:
05 2022

Historique:

received: 17 01 2022

accepted: 15 03 2022

pubmed: 29 4 2022

medline: 6 5 2022

entrez: 28 4 2022

Statut: ppublish

Résumé

Continuously emerging variants of concern (VOCs) sustain the SARS-CoV-2 pandemic. The SARS-CoV-2 Omicron/B.1.1.529 VOC harbours multiple mutations in the spike protein associated with high infectivity and efficient evasion from humoral immunity induced by previous infection or vaccination. By performing in-depth comparisons of the SARS-CoV-2-specific T-cell epitope repertoire after infection and messenger RNA vaccination, we demonstrate that spike-derived epitopes were not dominantly targeted in convalescent individuals compared to non-spike epitopes. In vaccinees, however, we detected a broader spike-specific T-cell response compared to convalescent individuals. Booster vaccination increased the breadth of the spike-specific T-cell response in convalescent individuals but not in vaccinees with complete initial vaccination. In convalescent individuals and vaccinees, the targeted T-cell epitopes were broadly conserved between wild-type SARS-CoV-2 variant B and Omicron/B.1.1.529. Hence, our data emphasize the relevance of vaccine-induced spike-specific CD8

Identifiants

DOI: 10.1038/s41564-022-01106-y PMID: 35484232 PMC: PMC9064790

pubmed: 35484232

doi: 10.1038/s41564-022-01106-y

pii: 10.1038/s41564-022-01106-y

pmc: PMC9064790

doi:

Substances chimiques

COVID-19 Vaccines 0

Epitopes, T-Lymphocyte 0

RNA, Messenger 0

Spike Glycoprotein, Coronavirus 0

spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

675-679

Informations de copyright

Références

Ferretti, A. P. et al. Unbiased screens show CD8

doi: 10.1016/j.immuni.2020.10.006

Hu, C. et al. Identification of cross-reactive CD8

doi: 10.1016/j.gendis.2021.05.006

Kared, H. et al. SARS-CoV-2-specific CD8

doi: 10.1172/JCI145476

Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74–85 (2021).

doi: 10.1038/s41590-020-00808-x

Saini, S. K. et al. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8

doi: 10.1126/sciimmunol.abf7550

Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8

doi: 10.1038/s41591-020-01143-2

Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe 29, 1076–1092 (2021).

doi: 10.1016/j.chom.2021.05.010

Lineburg, K. E. et al. CD8

doi: 10.1016/j.immuni.2021.04.006

Nguyen, T. H. O. et al. CD8

doi: 10.1016/j.immuni.2021.04.009

Peng, Y. et al. An immunodominant NP

doi: 10.1038/s41590-021-01084-z

Kang, L. et al. A selective sweep in the Spike gene has driven SARS-CoV-2 human adaptation. Cell 184, 4392–4400.e4 (2021).

doi: 10.1016/j.cell.2021.07.007

Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27, 671–680.e2 (2020).

doi: 10.1016/j.chom.2020.03.002

Shomuradova, A. S. et al. SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors. Immunity 53, 1245–1257.e5 (2020).

doi: 10.1016/j.immuni.2020.11.004

Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med. 2, 100204 (2021).

doi: 10.1016/j.xcrm.2021.100204